VRTXHealthcare · BiotechnologyThe 32 Wall Street analysts covering Vertex Pharmaceuticals, Inc. hold a median 12-month price target of $578 — +15.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 15 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Vertex Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (28): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VRTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.7% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $570 → $576 |
| 28 Sept 2026 | UBS | Maintains | Buy | — |
| 28 Sept 2026 | UBS | Maintains | Buy | $585 → $615 |
| 11 Sept 2026 | JP Morgan | Reinstates | Overweight | $515 → $560 |
| 2 Sept 2026 | Morgan Stanley | Reinstates | Overweight | $665 |
| 5 Aug 2026 | Barclays | Maintains | Overweight | $615 → $617 |
| 5 Aug 2026 | Barclays | Maintains | Overweight | — |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | $560 → $565 |
| 5 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Hold | $436 → $442 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 4 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 4 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $590 → $595 |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | $525 → $550 |
| 4 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 13 July 2026 | Truist Securities | Maintains | Buy | $542 → $560 |
| 13 July 2026 | Truist Securities | Maintains | Buy | — |
| 13 July 2026 | UBS | Maintains | Buy | $545 → $585 |
| 13 July 2026 | UBS | Maintains | Buy | — |
| 7 July 2026 | Baird | Maintains | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRTX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, Vertex Pharmaceuticals, Inc. returned +22.3% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 14% of US stocks
Cheaper than 15% of US stocks
Cheaper than 11% of US stocks
Higher than 58% of US stocks
Higher than 43% of US stocks
Higher than 94% of US stocks
Higher than 91% of US stocks
Higher than 92% of US stocks
Higher than 84% of US stocks
Higher than 95% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vertex Pharmaceuticals, Inc. has a market value of $128.9B and an enterprise value of $123.1B.
Revenue in the twelve months to 30 June 2026: $12.6B. The latest quarter grew 12.5% year on year.
Net income over the same four quarters: $4.4B, a 35.0% net margin.
Diluted earnings per share, trailing twelve months: $17.18.
Free cash flow in the twelve months to 30 June 2026: $3.8B.
Vertex Pharmaceuticals, Inc. spent $2.3B on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 29.5×; forward P/E: 25.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vertex Pharmaceuticals, Inc. employs 6,400 people — $2.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vertex Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vertex Pharmaceuticals has recently received considerable attention from Zacks.com users, prompting a reminder to consider facts that could affect the stock’s prospects.
Why it matters — VRTX watchers may want to review the factors relevant to the company’s stock prospects.
Vertex Pharmaceuticals closed at $508.75, up 2.06% from its previous close. The headline says the stock rose more than the overall market.
Why it matters — VRTX watchers may note the stock's daily gain and its performance relative to the market.
Vertex’s most recent acquisition added promising products in the hormone-disorder field. The excerpt says these products could eventually become meaningful growth drivers for the company.
Why it matters — VRTX watchers may want to note the potential for hormone-disorder products to broaden the company’s future growth sources beyond cystic fibrosis.
The Motley Fool compares Moderna’s expansion into RSV and oncology with Vertex’s cystic fibrosis market position and diversification into gene therapy and pain management.
Why it matters — The comparison highlights Vertex’s established cystic fibrosis business and its efforts to broaden into other treatment areas.
Biotechnology stocks are showing signs of renewed recovery amid increased pharmaceutical M&A activity and investor interest in drug-development pipelines. The excerpt says big pharma acquisitions are reaching record highs as companies address impending patent cliffs.
Why it matters — VRTX watchers may note the broader biotech recovery and acquisition activity, though the excerpt does not describe a company-specific development.
The 32 Wall Street analysts covering Vertex Pharmaceuticals, Inc. have a median 12-month price target of $578, with estimates ranging from $350 to $667. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 32 analysts covering Vertex Pharmaceuticals, Inc., 26 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Vertex Pharmaceuticals, Inc. 76 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Oct 2026, Vertex Pharmaceuticals, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).
No one can know that. What the data says: the median 12-month target from 32 analysts implies +15.7% from the last close, and Ticker Nerd's factor model ranks Vertex Pharmaceuticals, Inc. 76 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vertex Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $350 to $667 over the next 12 months.
Vertex Pharmaceuticals, Inc. returned +22.3% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX.
The most recent item we track (Zacks Investment Research, 16 Oct 2026): "Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?". Vertex Pharmaceuticals has recently received considerable attention from Zacks.com users, prompting a reminder to consider facts that could affect the stock’s prospects.
Vertex Pharmaceuticals Incorporated Common Stock represents ownership in Vertex Pharmaceuticals Incorporated, a global biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company’s current portfolio is centered on cystic fibrosis therapies and has expanded into additional specialty disease areas through products such as CASGEVY and JOURNAVX. Vertex serves patients across the United States, Europe, and other international markets, with a business model that combines specialized research, regulatory development, manufacturing, and commercialization capabilities. The company is known for operating in highly scientific and tightly regulated therapeutic markets, where innovation, clinical expertise, and product execution are central to its role. Vertex Pharmaceuticals Incorporated Common Stock is used by investors to track and participate in the performance of a biotechnology business with a strong presence in specialty pharmaceuticals and advanced medicine development.
CEO Dr. Reshma Kewalramani FASN, M.D. · 6,400 employees · United States · https://www.vrtx.com
